Latest news with #LeerinkPartners
Business Insider
a day ago
- Business
- Business Insider
Leerink Partners Sticks to Their Hold Rating for Humana (HUM)
Leerink Partners analyst Whit Mayo reiterated a Hold rating on Humana yesterday and set a price target of $271.00. The company's shares closed yesterday at $220.41. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Mayo is a 3-star analyst with an average return of 1.7% and a 46.84% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Universal Health, Tenet Healthcare, and UnitedHealth. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Humana with a $289.25 average price target, representing a 31.23% upside. In a report released yesterday, Barclays also downgraded the stock to a Hold with a $268.00 price target. The company has a one-year high of $406.09 and a one-year low of $206.87. Currently, Humana has an average volume of 1.75M.
CNBC
3 days ago
- Health
- CNBC
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Bristol Myers Squibb and Pfizer on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount. The move comes as the Trump administration ramps up pressure on the pharmaceutical industry to cut drug prices, and threatens to impose sweeping tariffs on pharmaceuticals imported into the U.S. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly cost from a list price of around $606 to $346. Starting Sept. 8, uninsured, underinsured and self-pay patients will be able to purchase the medicine directly from the Eliquis 360 Support program, which will ship their prescriptions directly to their homes. But the discounted price of Eliquis is still more than nine times the average monthly out-of-pocket cost of $38 paid by patients who are commercially insured. The price under the new program is also significantly higher than the $231 per month price that Medicare negotiated under a provision of the Biden administration's Inflation Reduction Act. That negotiated price is set to take effect next year. The negotiated price is what Medicare will pay for Eliquis, and does not set what Medicare patients will pay for the drug now or in the future, Bristol Myers Squibb and Pfizer said in a joint statement. They added that the negotiated price does not reflect "the substantial clinical and economic value of this essential medicine." More than 90% of Eliquis prescriptions in the U.S. are currently covered through insurance. But Bristol Myers Squibb and Pfizer said the new effort aims to expand access to the treatment, reduce out-of-pocket costs for patient and provide transparent pricing for a different group of patients. "This program passes more savings directly to patients and demonstrates our continued focus on identifying innovative solutions that foster the best outcomes for each individual while prioritizing access to care," said Bristol Myers Squibb CEO Chris Boerner. In a note on Thursday, Leerink Partners analyst David Risinger said he believes the move came in response to Trump's plan to lower U.S. drug costs by linking prices to those paid in other developed countries. The president signed an executive order on that plan in May. Risinger said the drugmakers already offer hefty rebates on Eliquis to pharmacy benefit managers, so the firm does not expect the program to create a "net pricing headwind" for Bristol Myers Squibb and Pfizer.
Globe and Mail
4 days ago
- Business
- Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Alkermes (ALKS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie (ABBV – Research Report) and Alkermes (ALKS – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. AbbVie (ABBV) Leerink Partners analyst David Risinger maintained a Buy rating on AbbVie on July 10. The company's shares closed last Monday at $191.52. According to Risinger is a 5-star analyst with an average return of 9.1% and a 54.3% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Centessa Pharmaceuticals, and Vertex Pharmaceuticals. ;'> AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $212.00, implying a 10.6% upside from current levels. In a report issued on June 30, William Blair also maintained a Buy rating on the stock. Alkermes (ALKS) Leerink Partners analyst Marc Goodman maintained a Hold rating on Alkermes on July 11. The company's shares closed last Monday at $29.69. According to Goodman is a 4-star analyst with an average return of 4.5% and a 47.0% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, ACADIA Pharmaceuticals, and Avadel Pharmaceuticals. ;'> Alkermes has an analyst consensus of Moderate Buy, with a price target consensus of $40.00, representing a 32.5% upside. In a report issued on July 7, RBC Capital also maintained a Hold rating on the stock with a $40.00 price target.
Globe and Mail
4 days ago
- Business
- Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Stoke Therapeutics (STOK)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLY – Research Report) and Stoke Therapeutics (STOK – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Stoke Therapeutics (STOK) Leerink Partners analyst Marc Goodman maintained a Buy rating on Stoke Therapeutics on July 10. The company's shares closed last Monday at $12.06. According to Goodman is a 4-star analyst with an average return of 4.5% and a 47.0% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, ACADIA Pharmaceuticals, and Avadel Pharmaceuticals. ;'> Stoke Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $24.80, representing a 109.6% upside. In a report issued on July 1, Needham also maintained a Buy rating on the stock with a $22.00 price target.
Business Insider
12-07-2025
- Business
- Business Insider
Icon (ICLR) Gets a Buy from Leerink Partners
Leerink Partners analyst Michael Cherny reiterated a Buy rating on Icon on July 9. The company's shares closed yesterday at $150.52. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Cherny is a 4-star analyst with an average return of 4.7% and a 54.30% success rate. Cherny covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Cardinal Health, and CVS Health. In addition to Leerink Partners, Icon also received a Buy from Truist Financial's Jailendra Singh in a report issued on July 9. However, on June 25, Barclays maintained a Hold rating on Icon (NASDAQ: ICLR). ICLR market cap is currently $12.28B and has a P/E ratio of 16.38. Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ICLR in relation to earlier this year.
